The funding round was led by Anglia Capital Group alongside the New Anglia Local Enterprise Partnership and the Low Carbon Innovation Fund.
"Anglia Capital Group is delighted to have had the opportunity to work with Health Enterprise East on the first spinout from the Norfolk and Norwich Hospital. Our members led the investment round because of the exciting potential for this technology in cancer surgery and were strongly supported by matching investment from our partner, the New Anglia Local Enterprise Partnership."
The follow-on investment will fund the commercial launch of new pancreatic and lung stem cell products.
"In a short space of time, DefiniGEN has undergone rapid development, securing growing sales with global pharma companies. We are delighted to have raised the funds that will allow us to deliver new market-leading products to our customers and assist them in developing therapies for the global healthcare challenges we face today such as diabetes and liver disease."
The investment round was led by an Asian corporate investor alongside existing backers to fund the commercial launch of Cyto-Mine.
"Sphere Fluidics Limited has recently successfully developed an alpha-version of its single cell analysis and characterization system (Cyto-Mine® for the biopharmaceutical discovery and development market. We have also convinced several leading biopharmaceutical companies to fund development of this system – indicating the global potential of the product. This new funding will used to develop the manufactured version of Cyto-Mine® (see image below) and enable its commercial launch later this year. This system is transformational for the Biopharmaceutical market."
Origin Capital joins syndicate to back genome editing software developer.
"We are delighted to have supported DTG. Although founded relatively recently, the business is a leader in this rapidly-growing field, and has already built commercial relationships with a number of important industry players."
